Select publications

EGFR inhibitors

Yang JC et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015;16(2):141-51. Abstract

Lee CK et al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: A meta-analysis. J Clin Oncol 2015;33(17):1958-65. Abstract

Soria JC et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial. Lancet Oncol 2015;16(8):990-8. Abstract

Park K et al. ASPIRATION: First-line erlotinib (E) until and beyond RECIST progression (PD) in Asian patients (pts) with EGFR mutation-positive (mut+) NSCLC. Proc ESMO 2014;Abstract 1223O.

Janjigian YY et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov 2014;4(9):1036-45. Abstract

Jänne PA et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015;372(18):1689-99. Abstract

Ramalingam SS et al. AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort. Proc ASCO 2015;Abstract 8000.

Sequist LV et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015;372(18):1700-9. Abstract

Sequist LV et al. Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). Proc ASCO 2015;Abstract 8001.

Kelly K et al. A randomized, double-blind Phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer: RADIANT results. Proc ASCO 2014;Abstract 7501.

Shepherd FA et al. Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients with tumors carrying EGFR-sensitizing mutations from the RADIANT trial. Proc ASCO 2014;Abstract 7513.

ALCHEMIST: Adjuvant lung cancer enrichment marker identification and sequencing trial.

ALK and other targeted therapies

Kim DW et al. Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. Proc ASCO 2014;Abstract 8003.

Gadgeel SM et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014;15(10):1119-28. Abstract

ALEX: A randomized, phase III study of alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). NCT02075840

Drilon AE et al. Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers. Proc ASCO 2015;Abstract 8007.

Planchard D et al. Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). Proc ASCO 2015;Abstract 8006.

Checkpoint Inhibitors

Paz-Ares L et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). Proc ASCO 2015;Abstract LBA109.

Rizvi NA et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol 2015;16(3):257-65. Abstract

Spigel DR et al. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). Proc ASCO 2015;Abstract 8009.

Brahmer J et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.N Engl J Med 2015;373(2):123-35. Abstract

Garon EB et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372(21):2018-28. Abstract

Spira AI et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). Proc ASCO 2015;Abstract 8010.

Rizvi NA et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). Proc ASCO 2015;Abstract 803.

A phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer. NCT02273375

A phase III, open-label, randomized study to investigate the efficacy and safety of MPDL3280A (anti-PD-L1 antibody) compared with best supportive care following adjuvant cisplatin-based chemotherapy in PD-L1-selected patients with completely resected stage Ib-IIIa non-small cell lung cancer. NCT02486718

Antonia SJ et al. Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. Proc ASCO 2015;Abstract 3014.

Planchard D et al. A phase III study of MEDI4736 (M), an anti-PD-L1 antibody, in monotherapy or in combination with tremelimumab (T), versus standard of care (SOC) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who have received at least two prior systemic treatment regimens (ARCTIC). Proc ASCO 2015;Abstract TPS8104.

Patnaik A et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. Proc ASCO 2015;Abstract 8011.

Rizvi N et al. Safety and efficacy of first-line nivolumab (anti-programmed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC). Proc IASLC 2015;Abstract Oral02.05.

Ott P et al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. Proc ASCO 2015;Abstract 7502.

Antonia SJ et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. Proc ASCO 2015;Abstract 7503.

Chemotherapeutic approaches with/without targeted biologic agents

Senan S et al. Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (pem), cisplatin (cis) or etoposide (eto), cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC). Proc ASCO 2015;Abstract 7506.

Garon EB et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384(9944):665-73. Abstract

Thatcher N et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015;16(7):763-74. Abstract

Paz-Ares L et al. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): An open-label, randomised, controlled phase 3 study. Lancet Oncol 2015;16(3):328-37. Abstract

Langer CJ et al. Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Analysis of safety and efficacy in patients with renal impairment. Clin Lung Cancer 2015;16(2):112-20. Abstract

Zalcman G et al. Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in malignant pleural mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial. Proc ASCO 2015;Abstract 7500.